Time to Buy Cerus Corporation (CERS) After The Completion of This Double Top?

September 16, 2018 - By Christine McCrea

Investors sentiment decreased to 1.43 in 2018 Q2. Its down 0.41, from 1.84 in 2018Q1. It is negative, as 12 investors sold Cerus Corporation shares while 30 reduced holdings. 23 funds opened positions while 37 raised stakes. 70.73 million shares or 2.38% more from 69.09 million shares in 2018Q1 were reported.
Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Cerus Corporation (NASDAQ:CERS). Int Incorporated accumulated 84,351 shares. Price T Rowe Assoc Md has 53,433 shares. Winch Advisory Serv Limited Liability Corp owns 200 shares. Parametric Portfolio Associates Ltd Liability holds 0% of its portfolio in Cerus Corporation (NASDAQ:CERS) for 98,932 shares. Ardsley Advisory Partners accumulated 80,000 shares. Janney Montgomery Scott Limited Liability Company reported 0% stake. Gp One Trading Ltd Partnership stated it has 56,898 shares or 0% of all its holdings. 77,931 were accumulated by Citigroup. Moreover, Schwab Charles Inc has 0% invested in Cerus Corporation (NASDAQ:CERS) for 678,414 shares. Great West Life Assurance Com Can owns 8,200 shares. Caprock Grp, a Idaho-based fund reported 12,000 shares. Amalgamated Natl Bank has invested 0% in Cerus Corporation (NASDAQ:CERS). 17,355 were accumulated by Brown Advisory Inc. Shufro Rose Limited Liability has 16,000 shares for 0.01% of their portfolio.

Since May 11, 2018, it had 0 buys, and 10 sales for $2.94 million activity. $375,005 worth of stock was sold by Green Kevin Dennis on Tuesday, August 28. On Friday, May 11 Benjamin Richard J sold $57,722 worth of Cerus Corporation (NASDAQ:CERS) or 8,631 shares. The insider SCHULZE GAIL sold 52,500 shares worth $349,125. The insider ANDERSON TIMOTHY B sold $152,950.

The chart of Cerus Corporation (CERS) shows a double top with $7.76 target or 7.00 % above today’s $7.25 share price. The 6 months chart pattern indicates low risk for the $970.15 million company. It was reported on Sep, 16 by Finviz.com. If the $7.76 price target is reached, the company will be worth $67.91 million more. Double tops are rare but powerful chart patterns.

The stock decreased 1.23% or $0.09 during the last trading session, reaching $7.25. About 704,216 shares traded. Cerus Corporation (NASDAQ:CERS) has risen 168.03% since September 16, 2017 and is uptrending. It has outperformed by 152.41% the S&P500.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on November, 1. They expect $-0.11 EPS, up 8.33 % or $0.01 from last year’s $-0.12 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 10.00 % negative EPS growth.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $970.15 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: